Our Pipeline

About GDD3898

GDD3898 is a clinical-stage Phase 2 drug candidate being developed by Lipidio Pharmaceuticals. Lipidio plans to leverage existing efficacy and human safety data for GDD3898 and conduct new clinical studies to strengthen support for its therapeutic potential in multiple indications.